Figure 2. Glibenclamide reverses cardiac hypertrophy in SUR2^wt/AV mice.

(A) Left: Representative hearts from placebo-implanted WT (black), placebo-implanted SUR2^wt/AV (orange), and approximately 19 mg/kg/day glibenclamide pellet implanted SUR2^wt/AV (brown) mice. Right: Summary of heart size (weight normalized to tibia length; HW/TL) for WT and SUR2^wt/AV mice implanted with either placebo pellets (Glib = 0), or pellets releasing approximately 1 mg/kg/day and approximately 19 mg/kg/day. (B) Summary of MAP in anesthetized placebo-pellet (Glib = 0) and approximately 19 mg/kg/day glibenclamide pellet–implanted WT and SUR2^wt/AV mice. In all experiments, pellets were implanted at 8 weeks of age, and phenotypes were assessed 4 weeks later. (C) Systemic vascular resistance (SVR) and (D) cardiac index in placebo-implanted WT mice and placebo- or glibenclamide pellet–implanted SUR2^wt/AV mice. (E) Gomori-stained left ventricular free wall sections. Scale bars: 500 μm. (F) Ejection fraction of placebo-implanted WT mice and placebo- or glibenclamide pellet–implanted SUR2^wt/AV mice. Carotid artery compliance measurements from (G) placebo-implanted or approximately 19 mg/kg/day glibenclamide pellet–implanted WT and SUR2^wt/AV mice, or (H) WT, SUR2^wt/AV, and SMDN^wt/AV mice. Individual data points are represented as open circles, bars show mean ± SEM. Statistical significance was determined by 1-way ANOVA (A–F) and 2-way ANOVA (G and H) with subsequent post hoc Tukey’s test for pairwise comparison. *P < 0.05; **P < 0.01 from pairwise post hoc Tukey’s test. For G and H, color-coded statistical significance indicators are shown for comparison with placebo-implanted WT mice (black).